Adjuvant Anlotinib Displays Efficacy in High-Grade Soft Tissue Sarcoma
Adjuvant anlotinib was safe and led to a DFS benefit vs surgery alone in completely resected high-grade soft tissue sarcoma.
Related Articles
NAPOLI-3 Analysis Exposes Characteristics of Long-Term PDAC Survivors Treated With NALIRIFOX
A post hoc analysis of NAPOLI-3 reveals insights on long-term survivors with pancreatic cancer who received NALIRIFOX.
First-Line Fruquintinib Combo May Offer New Treatment Strategy in ESCC
A fruquintinib regimen appeared safe and effective when used as a frontline treatment in esophageal squamous cell carcinoma.
Ipatasertib Plus Fulvestrant Demonstrates Significant PFS Benefit in ER+/HER2– Metastatic Breast Cancer
Ipatasertib plus fulvestrant extended PFS vs placebo plus fulvestrant in patients with ER-positive/HER2-negative metastatic breast cancer.
Dr Curtis on Cyclophosphamide GVHD Prophylaxis in Matched Donor Transplant
David Curtis, MBBS, PhD, FRACP, FRCPA, discusses the use of post-transplant cyclophosphamide GVHD prophylaxis in matched donor peripheral blood SCT.
D-VRd Retains Its Role as a Potential Standard of Care for Transplant-Ineligible Multiple Myeloma
D-VRd led to deeper and more durable responses that translated into improved PFS vs VRd alone in transplant-ineligible patients with multiple myeloma.
First-Line T-DXd Plus Pertuzumab Yields PFS Benefit in HER2+ Advanced Breast Cancer
Trastuzumab deruxtecan plus pertuzumab produced a statistically significant PFS improvement in frontline HER2-positive advanced breast cancer.
How Firsthand Breast Cancer Experience Shaped a Surgeon’s Mission to Educate Colleagues and Empower Patients: With D. Ross Camidge, MD, PhD; and Liz O’Riordan, FRCS, PhD
D. Ross Camidge, MD, PhD sat down with Liz O’Riordan, FRCS, PhD, who describes herself as a breast surgeon who has had breast cancer.
Optimizing TKI Selection and Sequencing Strategies in Advanced GIST Beyond First-Line Therapy
Experts discuss optimizing TKI selection and sequencing strategies for advanced gastrointestinal stromal tumors (GIST) beyond first-line therapy, focusing on the latest clinical data, molecular characterization,…
Subcutaneous Daratumumab Approaches EU Approval in High-Risk Smoldering Myeloma
The EMA’s CHMP has issued a positive opinion regarding the use of subcutaneous daratumumab in high-risk smoldering myeloma.
Relacorilant/Nab-Paclitaxel Is Associated With Survival Improvement in Platinum-Resistant Ovarian Cancer After Short Platinum-Free Interval
Relacorilant plus nab-paclitaxel improved survival in platinum-resistant ovarian cancer with a primary platinum-free interval of 1 to 6 months.